Note 8 - Share-based Compensation (Tables)

9 Months Ended

Sep. 30, 2021

Notes Tables

Share-based Payment Arrangement, Option, Activity [Table Text Block]

	Nine Months Ended
	September 30, 2021
	Shares			Wtd. Avg. Exercise Price
Outstanding as of beginning of year		844,455		$	2.00
Exercised		(131,590	)		1.48
Forfeited		(1,146	)		5.69
Expired		(35,714	)		1.73
Outstanding as of September 30, 2021		676,005		$	2.12
Stock options exercisable as of September 30, 2021		671,964		$	2.11

	Nine Months Ended
	September 30, 2021
	Shares			Wtd. Avg. Exercise Price
Outstanding as of beginning of year		686,001		$	1.64
Exercised		(501,075	)		1.64
Outstanding as of September 30, 2021		184,926		$	1.64
Stock options exercisable as of September 30, 2021		184,926		$	1.64

Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]

	Nine Months Ended
	September 30, 2021
	Shares			Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of year		930,854		$	19.31
Granted		751,363			47.50
Vested		(241,590	)		15.97
Forfeited		(79,079	)		34.86
Non-vested as of September 30, 2021		1,361,548		$	34.56

	Nine Months Ended
	September 30, 2021
	Shares			Wtd. Avg. Grant Date Fair Value
Outstanding as of beginning of year		224,774		$	19.20
Granted		152,665			30.85
Vested		(231,268	)		26.98
Non-vested as of September 30, 2021		146,171		$	20.78

Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]

	Three Months Ended				Nine Months Ended
	September 30,				September 30,
	2021		2020		2021		2020
Research and development costs	$	551	$	291	$	1,171	$	687
Sales and marketing costs		560		256		1,012		581
General and administrative costs		3,015		868		5,662		2,144
Cost of revenue		742		145		1,047		406
Total	$	4,868	$	1,560	$	8,892	$	3,818